Visualizing coronary calcium is associated with improvements in adherence to statin therapy.

[1]  Y. Arad,et al.  Objectives Background Methods Results Conclusions , 2022 .

[2]  Marc B Blatt.  In-hospital initiation of lipid-lowering therapy. , 2004, Critical pathways in cardiology.

[3]  A. Fendrick,et al.  Suboptimal statin adherence and discontinuation in primary and secondary prevention populations , 2004, Journal of General Internal Medicine.

[4]  M. Mamdani,et al.  Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. , 2004, JAMA.

[5]  R. Detrano,et al.  Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. , 2004, JAMA.

[6]  R. Redberg.  Coronary artery calcium and cardiac events. , 2003, Circulation.

[7]  M. Budoff,et al.  Electron beam CT versus helical CT scans for assessing coronary calcification: current utility and future directions. , 2003, American heart journal.

[8]  D. Berman,et al.  Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. , 2003, Radiology.

[9]  Kiang Liu,et al.  Electron-Beam Tomography Coronary Artery Calcium and Cardiac Events: A 37-Month Follow-Up of 5635 Initially Asymptomatic Low- to Intermediate-Risk Adults , 2003, Circulation.

[10]  P. Greenland.  Improving risk of coronary heart disease: can a picture make the difference? , 2003, JAMA.

[11]  P. O'Malley,et al.  Impact of electron beam tomography, with or without case management, on motivation, behavioral change, and cardiovascular risk profile: a randomized controlled trial. , 2003, JAMA.

[12]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[13]  Vijay Nambi,et al.  Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. , 2002, The American journal of medicine.

[14]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[15]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[16]  R. Hays,et al.  A Comparison Study of Multiple Measures of Adherence to HIV Protease Inhibitors , 2001, Annals of Internal Medicine.

[17]  R. Califf,et al.  Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study , 2001, The Lancet.

[18]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[19]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[20]  P. Giral,et al.  Factors associated with low compliance with lipid‐lowering drugs in hyperlipidemic patients , 2000, Journal of clinical pharmacy and therapeutics.

[21]  Y. Arad,et al.  Prediction of coronary events with electron beam computed tomography. , 2000, Journal of the American College of Cardiology.

[22]  R. Hays,et al.  Measuring Adherence to Antiretroviral Medications in Clinical Trials , 2000, HIV clinical trials.

[23]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[24]  Philip Greenland,et al.  Prevention Conference V Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Executive Summary , 2000 .

[25]  V. Fuster,et al.  Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. , 2000, Circulation.

[26]  M. Hill,et al.  The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. , 1997, Circulation.

[27]  R. Straka,et al.  Patient Self‐Reporting of Compliance Does Not Correspond with Electronic Monitoring: An Evaluation Using Isosorbide Dinitrate as a Model Drug , 1997, Pharmacotherapy.

[28]  G. Diamond,et al.  Does coronary artery screening by electron beam computed tomography motivate potentially beneficial lifestyle behaviors? , 1996, The American journal of cardiology.

[29]  D. Mant,et al.  Motivational effect of cholesterol measurement in general practice health checks. , 1992, The British journal of general practice : the journal of the Royal College of General Practitioners.

[30]  K. Glanz,et al.  Health behavior and health education : theory, research, and practice , 1991 .

[31]  C. Viscoli,et al.  Treatment adherence and risk of death after a myocardial infarction , 1990, The Lancet.

[32]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[33]  M. Robin DiMatteo,et al.  Achieving Patient Compliance , 1982 .

[34]  I. Rosenstock.  The health belief model and nutrition education. , 1982, Journal of the Canadian Dietetic Association.